查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球呼吸道感染診斷市場 - 2022-2029
市場調查報告書
商品編碼
1143389

全球呼吸道感染診斷市場 - 2022-2029

Global Respiratory Infectious Disease Diagnostics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預計 2021 年呼吸道感染診斷的市場規模將達到 639 億美元，在預測期間（2022-2029 年）以 1.8% 的複合年增長率增長。

呼吸道感染是由感染呼吸系統（包括肺、咽喉和呼吸道）的病毒、細菌和其他微生物引起的。感染通常通過通常在打噴嚏、咳嗽和大笑時排出的粘液和唾液傳播。還有許多空氣中的飛沫和細菌可以在旅行中傳播並導致呼吸道感染。此外，有些人因接觸留在表面的微生物或接觸受污染的手而被感染。

市場動態

市場受到呼吸系統疾病上升和產品技術進步的推動。

預計呼吸系統疾病負擔加重和產品技術進步將推動市場增長。

慢性阻塞性肺病是一種進行性肺病，會導致氣流減少。根據世界衛生組織 (WHO) 的數據，90% 的 COPD 死亡發生在低收入和中等收入國家。根據全球疾病負擔研究，全球已報告約 2.51 億例 COPD 病例。由於老齡化進程和人們生活方式的改變，預計未來會增加。因此，早期診斷和早期治療極為重要，有望推動市場增長。

最近隨著 COVID-19 感染在全球蔓延的大流行是預計在預測期內增加診斷需求的主要因素。根據目前的統計數據，2020 年 4 月全球有 608 萬人感染了 COVID-19 疾病，這可能會影響對快速診斷檢測的需求。預計這一因素將在預測期內推動呼吸道感染診斷市場的發展。

2020 年 1 月發布的數據顯示，全球有 2,519 例實驗室適合的中東呼吸綜合徵 (MERS) 病例，其中包括 866 例相關死亡病例。大部分報告病例發生在沙特阿拉伯（2121 例），包括 788 例相關死亡，病死率高達 37.1%。此外，COVID-19 大流行需要更快速的診斷。據統計，2020年5月，全球報告了近608萬例COVID-19病例，增加了對該病早期診斷的需求。這一因素將在預測期內推動市場增長。

據推測，慢性阻塞性肺病（如慢性支氣管炎、肺氣腫和哮喘）以及肺病（如肺結核和肺炎）的負擔激增，將推動呼吸道感染診斷市場的增長。此外，下呼吸道感染的增加將增加對早期檢測的需求，進一步推動對診斷測試的需求。預計這些因素將在預測期內推動市場增長。

嚴格的監管框架和不利的報銷政策是阻礙市場增長的主要因素。

但是，嚴格的監管框架、不利的報銷政策以及患者意識低下將阻礙預測期內的市場增長。

COVID-19 影響分析

根據緊急使用授權，截至 2022 年 8 月，美國 FDA 已批准 439 項測試。 （歐盟）。用於檢測 SARS-CoV-2 的新分子診斷測試充斥著市場。預計市場將受到快速的技術進步、便攜性和成本效益的推動，以獲得準確的結果。佳能醫療系統的 CT 系統“Aquilion Prime SP”於 2020 年 4 月推出，用於快速識別病毒感染。該產品包括一個集成的去污工具，該工具使用自動 UV-C 技術對整個設備在用於其他患者後進行消毒。

行業分析

全球呼吸道感染診斷市場根據波特五力、監管分析、報銷分析、供應鏈分析、定價分析和技術進步等各種行業因素對市場進行了深入分析。我來了。

全球呼吸道感染診斷市場 - 細分分析

預計冠狀病毒部分將佔全球血壓監測設備市場的最大市場份額

冠狀病毒傳染病部門佔最大的市場份額。據世界衛生組織稱，截至 2020 年 3 月 27 日，SARS-CoV-2 已傳播到 150 多個國家，確診病例超過 46 萬例，死亡病例超過 2 萬例。根據 2020 年 3 月在世界經濟論壇上發表的一篇文章，在美國住院的 500 人中，20% 的人年齡在 20-44 歲之間，18% 的人年齡在 45-54 歲之間。這一因素將在預測期內推動市場增長。

預計患有心血管疾病、慢性呼吸道疾病、高血壓和糖尿病等既往疾病的人的死亡率將高於平均水平。此外，據中國疾控中心稱，男性比女性更容易感染病毒並患重病。男性死亡率為 2.8%，女性死亡率為 1.7%。預計這些因素將在預測期內推動市場增長。

區域介紹

由於呼吸道疾病負擔的增加和吸煙率的上升，預計呼吸道感染診斷市場將以最高的複合年增長率增長，其中北美佔世界的大部分。

根據疾病控制和預防中心的數據，2018 年美國的哮喘患病率在男性中約為 6.2%，在女性中約為 9.1%。此外，據報導，美國約有 6.2% 的人患有慢性阻塞性肺病。預計這些因素將在預測期內推動市場增長。

採用快速診斷測試來快速診斷呼吸道感染也是預計擴大該地區呼吸道感染診斷市場的關鍵因素之一。據CDC統計，2020年5月，實時逆轉錄□（RT）-PCR診斷試劑盒可有效檢測呼吸道標本中的SARS-CoV-2病毒。美國食品和藥物管理局還於 2020 年 2 月為該測試提供了緊急使用授權 (EUA)。預計這些因素將在預測期內推動市場增長。

競爭格局

由於存在多個國際和本地市場，全球呼吸道感染診斷市場競爭激烈。產品多樣化、創收和不斷增長的機會使市場更具競爭力。 Abbott Laboratories、Thermo Fisher Scientific Inc.、Alere, Inc.、Koninklijke Philips N.V.、Cardinal Health、COSMED、Smiths Group plc、NIHON KOHDEN CORPORATION、Becton、Dickinson and Company、F. Hoffmann-La Roche AG. 已成為領先市場企業與主要參與者正在利用產品開發、新產品發布、市場擴張和產品多元化戰略來保持其市場地位。例如，2020 年 8 月，國際臨床診斷專家 Novacyt 宣布推出獲得 CE 標誌的聚合□鏈反應 (PCR) 呼吸檢測試劑盒 Winterplex。該測試面板設計用於任何開放式 PCR 平台，包括我們的快速便攜式 q32 儀器。

本報告提供了近 45+ 個市場數據表、40+ 個圖表和 180 頁有關全球呼吸道感染診斷市場的信息。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 第 3 章：按疾病類型劃分的市場細分
  • 按測試類型劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 呼吸系統疾病負擔加重
      • 技術進步
    • 約束因素
      • 嚴格的監管框架
  • 影響分析
  • 商機

第5章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 保險報銷分析

第6章按疾病類型

  • 冠狀病毒感染
  • 中東呼吸綜合徵 (MERS)
  • 支氣管哮喘
  • 慢性阻塞性肺疾病
  • 肺結核
  • 肺癌
  • 其他

第 7 章按測試類型

    • 圖像檢查
    • 機械檢查
      • 肺活量計
      • 峰值流量檢查
      • 血氣檢測
      • 肺功能檢查
      • 阻塞性睡眠呼吸暫停綜合徵診斷測試
    • 體外診斷測試
      • 即時檢測
      • 分子生物學診斷測試
    • 其他測試

第 8 章最終用戶

  • 醫院
  • 診斷中心
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 11 章公司簡介

  • 雅培實驗室
    • 公司簡介
    • 產品組合和描述
    • 主要發展狀況
    • 財務摘要
  • Becton Dickinson & Company
  • Thermo Fisher Scientific Inc
  • Alere, Inc
  • Koninklijke Philips N.V
  • Cardinal Health
  • COSMED
  • Smiths Group plc
  • NIHON KOHDEN CORPORATION
  • F. Hoffmann-La Roche AG.

第12章 全球呼吸道感染診斷市場-DataM

簡介目錄
Product Code: DMMD2675

Market Overview

Respiratory Infectious Disease Diagnostics Market size was valued US$ 63.9 billion in 2021 and is estimated to reach US$ YY billion by 2029, growing at a CAGR of 1.8% during the forecast period (2022-2029).

Respiratory infections are caused by virus, bacteria, and other microbes, which further infect the respiratory system including the lungs, throat, and airways. Spread of infections is often through mucus and saliva that is usually expelled when the person sneezes, coughs, or laughs. Few of the germs are also spread though droplets that spread through air and also spread through travelling, which causes respiratory infections. Furthermore, some people can be infected by touching the remaining microbes on the surface, or touching contaminated hands.

Market Dynamics

The market is driven is the rising burden of respiratory diseases and technological advancements in the products.

Rising burden of respiratory diseases and technological advancements in the products are expected to drive market growth

Chronic obstructive pulmonary disease is a progressive lung disorder which causes reduction in airflow. According to the World Health Organization, 90% of the COPD deaths occur in low- and middle-income countries. Approximately 251 million cases of COPD were reported globally as per the study of the Global Burden of Disease Study. It is expected to increase in the coming years due to increasing aging population and changing lifestyle of people. Therefore, early diagnosis and treatment is very important which is expected to boost the market growth.

Recent pandemic resulting into widespread COVID-19 infections across the globe is a major factor that is estimated to boost the demand for diagnosis during forecast period. As per current statistics, in April 2020, 6.08 million people across globe were infected with COVID-19 diseases, and this is likely to impact the need for rapid diagnostics testing. This factor is likely to boost the respiratory infectious diagnostics market during forecast period.

According to data published in January 2020, 2519 laboratory-conformed cases of Middle East respiratory syndrome (MERS), were reported, which includes 866 associated deaths globally. Majority of cases reported were from Saudi Arabia (2121 cases), including 788 related deaths with a higher fatality rate of 37.1%. Moreover, the emergence of COVID-19 pandemic has driven the demand for faster diagnosis. According to statistics, in May 2020, there were around 6.08 million COVID-19 cases reported globally, which boosts the need for early diagnosis of diseases. This factor will drive the growth of market in the forecast period.

Rapid rise in burden of chronic obstructive pulmonary disorders such as chronic bronchitis, emphysema, asthma, and other lung diseases such as tuberculosis, pneumonia, is estimated to boost the respiratory infectious disease diagnostics market. Furthermore, rising lower respiratory infectious disease drives the need for early detection, which further drivers the demand for diagnostics tests. This factor will drive the growth of market in the forecast period.

Stringent regulatory framework coupled with unfavorable reimbursement policies are one of the major factors hindering the growth of the market

However, a stringent regulatory framework coupled with unfavorable reimbursement policies and a low awareness rate among the patient population will hamper the growth of the market in the forecast period.

COVID-19 Impact Analysis

In accordance with Emergency Use of Authorization, the U.S. FDA had approved 439 tests as of August 2022. (EUAs). New molecular diagnostic tests for SARS-CoV-2 detection have flooded the market. The market is predicted to be driven by rapid technical improvements that produce accurate findings, portability, and cost-effectiveness. The Aquilion Prime SP CT system from Canon Medical Systems was introduced in April 2020 to identify viral infectious illnesses quickly. This product includes an integrated decontamination tool that sanitises the entire apparatus using automated UV-C technology after being used by additional patients.

Industry Analysis

The global respiratory infectious disease diagnostics market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, reimbursement analysis, supply chain analysis, pricing analysis, technological advancements etc.

Global Respiratory Infectious Disease Diagnostics Market - Segment Analysis

Coronavirus infections segment is expected to hold the largest market share in global blood pressure monitoring devices market

The coronavirus infections segment held the largest market share. According to the WHO, SARS-CoV-2 has spread to over 150 countries with over 460,000 confirmed cases and over 20,000 deaths as of 27th March 2020. According to an article published in the World Economic Forum in March 2020, among the 500 people being hospitalized in the U.S., 20% were aged between 20 to 44 years and 18 % were aged between 45-54 years. This factor would drive the growth of the market in the forecast period.

People with existing illnesses such as cardiovascular disease, chronic respiratory disease, hypertension, and diabetes are expected to experience a higher than average fatality rate. Moreover, according to the Chinese CDC, males are more vulnerable to becoming severely ill with the virus than women. The male fatality rate is 2.8% and the female fatality rate is 1.7%. This factor will drive the growth of market in the forecast period.

Geographical Presentation

North America dominated the global respiratory infectious disease diagnostics market and is expected to grow at the highest CAGR during the forecast period due to growing burden of respiratory diseases and higher prevalence of smoking.

According to the Centre for Disease Control and Prevention, in 2018, the prevalence of Asthma was found to be around 6.2% in male and 9.1% in female in the United States. Furthermore, around 6.2% of people were reported with chronic obstructive pulmonary diseases in the United States. Hence, these factors are expected to drive the growth of market in the forecast period.

Adoption of rapid diagnostics tests for faster diagnosis of respiratory infectious diseases is another key factor that is anticipated to augment the respiratory infectious disease diagnostics market in the region. As per CDC statistics, in May 2020, the Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panel is efficient in detecting the SARS-CoV-2 virus in respiratory specimens. The USFDA also offered its Emergency Use Authorization (EUA) for this test in February 2020. These factors are expected to drive the growth of market in the forecast period.

Competitive Landscape

The global respiratory infectious disease diagnostics market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Abbott Laboratories, Thermo Fisher Scientific Inc., Alere, Inc., Koninklijke Philips N.V., Cardinal Health, COSMED, Smiths Group plc, NIHON KOHDEN CORPORATION, Becton, Dickinson and Company, and F. Hoffmann-La Roche AG. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market. For instance, in August 2020, Novacyt an international specialist in clinical diagnostics, announces the launch of its CE-Mark approved polymerase chain reaction (PCR) respiratory test panel, Winterplex. The test panel is designed to be used on any open PCR platform, including the Company's rapid, portable q32 instrument.

The global respiratory infectious disease diagnostics market report will provide access to approximately 45+ market data table,, 40+ figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Test Type
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Burden of Respiratory Diseases
      • 4.1.1.2. Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Framework
  • 4.2. Impact Analysis
  • 4.3. Opportunity

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Reimbursement Analysis

6. By Disease Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.3. Market Attractiveness Index, By Disease Type
    • 6.3.1. Coronavirus Infections *
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 6.3.2. Middle East Respiratory Syndrome (MERS)
    • 6.3.3. Asthma
    • 6.3.4. Chronic Obstructive Pulmonary Disorder
    • 6.3.5. Tuberculosis
    • 6.3.6. Lung Cancer
    • 6.3.7. Others

7. By Test Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 7.3. Market Attractiveness Index, By Test Type
    • 7.3.1. Imaging Tests
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.3.2. Mechanical Tests
      • 7.3.2.1. Spirometry
      • 7.3.2.2. Peak Flow Test
      • 7.3.2.3. Blood Gas Test
      • 7.3.2.4. Pulmonary Function Test
      • 7.3.2.5. Obstructive Sleep Apnea Diagnostic Test
    • 7.3.3. In-vitro Diagnostic Tests
      • 7.3.3.1. Point-of-care Test
      • 7.3.3.2. Molecular Diagnostic Test
    • 7.3.4. Other Tests

8. By End-User

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 8.3. Market Attractiveness Index, By Application
    • 8.3.1. Hospitals
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3.2. Diagnostic Centers
    • 8.3.3. Others

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. U.S.
      • 9.4.6.2. Canada
      • 9.4.6.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. Germany
      • 9.5.6.2. U.K.
      • 9.5.6.3. France
      • 9.5.6.4. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.6.1. Brazil
      • 9.6.6.2. Argentina
      • 9.6.6.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.6.1. China
      • 9.7.6.2. India
      • 9.7.6.3. Japan
      • 9.7.6.4. Australia
      • 9.7.6.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Abbott Laboratories *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Developments
    • 11.1.4. Financial Overview
  • 11.2. Becton Dickinson & Company
  • 11.3. Thermo Fisher Scientific Inc
  • 11.4. Alere, Inc
  • 11.5. Koninklijke Philips N.V
  • 11.6. Cardinal Health
  • 11.7. COSMED
  • 11.8. Smiths Group plc
  • 11.9. NIHON KOHDEN CORPORATION
  • 11.10. F. Hoffmann-La Roche AG.

12. Global Respiratory Infectious Disease Diagnostics Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us